share_log

CVS Health | 424B2: Prospectus

CVS Health | 424B2: Prospectus

西維斯健康 | 424B2:募資說明書
美股SEC公告 ·  12/06 05:09

Moomoo AI 已提取核心訊息

On December 3, 2024, CVS Health announced the offering of $3 billion in junior subordinated notes, comprising $2.25 billion of 7.000% Series A notes due 2055 and $750 million of 6.750% Series B notes due 2054. The Series A notes will bear interest at 7.000% until March 10, 2030, and the Series B notes at 6.750% until December 10, 2034, with rates resetting based on the Five-year U.S. Treasury Rate plus a spread.The proceeds will be used for tender offers to repurchase existing senior notes, including those due in 2025 and 2040, and for general corporate purposes. The notes are unsecured and subordinated, ranking junior to existing senior debt. Interest payments can be deferred for up to 10 years.The offering is not contingent on the completion of the tender offers. The notes will not be listed on any securities exchange, and the offering is expected to close on December 10, 2024.
On December 3, 2024, CVS Health announced the offering of $3 billion in junior subordinated notes, comprising $2.25 billion of 7.000% Series A notes due 2055 and $750 million of 6.750% Series B notes due 2054. The Series A notes will bear interest at 7.000% until March 10, 2030, and the Series B notes at 6.750% until December 10, 2034, with rates resetting based on the Five-year U.S. Treasury Rate plus a spread.The proceeds will be used for tender offers to repurchase existing senior notes, including those due in 2025 and 2040, and for general corporate purposes. The notes are unsecured and subordinated, ranking junior to existing senior debt. Interest payments can be deferred for up to 10 years.The offering is not contingent on the completion of the tender offers. The notes will not be listed on any securities exchange, and the offering is expected to close on December 10, 2024.
2024年12月3日,CVS Health宣佈發行30億美元的初級次級次級票據,包括2055年到期的22.5億美元7.000%的A系列票據和2054年到期的7.5億美元6.750%的b系列票據。在2030年3月10日之前,A系列票據的利息將爲7.000%,在2034年12月10日之前,b系列票據的利息爲6.750%,利率將根據五年期美國國債利率加利差進行重置。所得款項將用於要約回購現有優先票據,包括2025年和2040年到期的優先票據,並用於一般公司用途。這些票據是無抵押的,是次要債券,排名低於現有的優先債務。利息支付最多可以延期10年。此次發行不以投標要約的完成爲條件。這些票據不會在任何證券交易所上市,發行預計將於2024年12月10日結束。
2024年12月3日,CVS Health宣佈發行30億美元的初級次級次級票據,包括2055年到期的22.5億美元7.000%的A系列票據和2054年到期的7.5億美元6.750%的b系列票據。在2030年3月10日之前,A系列票據的利息將爲7.000%,在2034年12月10日之前,b系列票據的利息爲6.750%,利率將根據五年期美國國債利率加利差進行重置。所得款項將用於要約回購現有優先票據,包括2025年和2040年到期的優先票據,並用於一般公司用途。這些票據是無抵押的,是次要債券,排名低於現有的優先債務。利息支付最多可以延期10年。此次發行不以投標要約的完成爲條件。這些票據不會在任何證券交易所上市,發行預計將於2024年12月10日結束。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息